Related Experiment Video

Updated: Oct 1, 2026

A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
08:38

A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition

Published on: July 21, 2023

The role of endothelin in the pathogenesis of heart failure

John R Teerlink1

  • 1Department of Cardiology, 111C, San Francisco VA Medical Center, 4150 Clement Street, San Francisco, CA 94121-1545, USA. johnt@itsa.ucsf.edu

Current Cardiology Reports
|April 19, 2002
PubMed

Insights

Endothelin plays a key role in chronic heart failure pathogenesis, causing vasoconstriction, hypertrophy, and fibrosis. While endothelin receptor antagonists showed promise in studies, clinical trials have not yet confirmed their therapeutic benefits.

Area of Science:

  • Cardiovascular Research
  • Molecular Medicine
  • Pathophysiology

Background:

  • Endothelin is a potent vasoconstrictor implicated in chronic heart failure.
  • The endothelin system is significantly upregulated in patients with heart failure.
  • Endothelin contributes to adverse cardiac remodeling, including hypertrophy and fibrosis.

Purpose of the Study:

  • To review the role of endothelin signaling in chronic heart failure pathogenesis.
  • To examine the mechanisms by which endothelin exerts its effects on cardiac and vascular tissues.
  • To evaluate the clinical efficacy of endothelin receptor antagonists in heart failure.

Main Methods:

  • Literature review of studies on endothelin in heart failure.
  • Analysis of endothelin signaling pathways and mechanisms of action.
  • Examination of preclinical and clinical trial data for endothelin receptor antagonists.

Main Results:

  • Endothelin mediates vasoconstriction, pathologic hypertrophy, fibrosis, and proarrhythmic effects.
  • Experimental studies demonstrated potential benefits of endothelin receptor antagonists.
  • Clinical trials investigating endothelin receptor antagonists have yielded disappointing results to date.

Conclusions:

  • Endothelin is a critical factor in chronic heart failure.
  • Further analysis of clinical trial data is needed to understand the discrepancy between experimental and clinical findings.
  • Future research should focus on refining therapeutic strategies targeting the endothelin system.

More Related Videos

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...